| Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes J Rosenstock, N Aggarwal, D Polidori, Y Zhao, D Arbit, K Usiskin, ... Diabetes care 35 (6), 1232-1238, 2012 | 528 | 2012 |
| Canagliflozin, a novel inhibitor of sodium glucose co‐transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose … S Sha, D Devineni, A Ghosh, D Polidori, S Chien, D Wexler, K Shalayda, ... Diabetes, Obesity and Metabolism 13 (7), 669-672, 2011 | 358 | 2011 |
| Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized … D Polidori, S Sha, S Mudaliar, TP Ciaraldi, A Ghosh, N Vaccaro, K Farrell, ... Diabetes care 36 (8), 2154-2161, 2013 | 339 | 2013 |
| Apparatus and method for computer modeling type 1 diabetes K Gadkar, H Kreuwel, T Paterson, D Polidori, S Ramanujan, LKM Shoda, ... US Patent App. 11/377,614, 2007 | 324 | 2007 |
| Efficacy and safety of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes RR Henry, P Thakkar, C Tong, D Polidori, M Alba Diabetes care 38 (12), 2258-2265, 2015 | 308 | 2015 |
| Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin JP Bilezikian, NB Watts, K Usiskin, D Polidori, A Fung, D Sullivan, ... The Journal of Clinical Endocrinology 101 (1), 44-51, 2016 | 289 | 2016 |
| Effect of the sodium glucose co‐transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus S Sha, D Polidori, T Heise, J Natarajan, K Farrell, SS Wang, D Sica, ... Diabetes, Obesity and Metabolism 16 (11), 1087-1095, 2014 | 269 | 2014 |
| Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models Y Liang, K Arakawa, K Ueta, Y Matsushita, C Kuriyama, T Martin, F Du, ... PloS one 7 (2), e30555, 2012 | 260 | 2012 |
| Sodium–glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside S Mudaliar, D Polidori, B Zambrowicz, RR Henry Diabetes care 38 (12), 2344-2353, 2015 | 258 | 2015 |
| Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in subjects with type 2 diabetes mellitus D Devineni, CR Curtin, D Polidori, MJ Gutierrez, J Murphy, S Rusch, ... The Journal of Clinical Pharmacology 53 (6), 601-610, 2013 | 246 | 2013 |
| How strongly does appetite counter weight loss? Quantification of the feedback control of human energy intake D Polidori, A Sanghvi, RJ Seeley, KD Hall Obesity 24 (11), 2289-2295, 2016 | 213 | 2016 |
| Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes WT Cefalu, K Stenlöf, LA Leiter, JPH Wilding, L Blonde, D Polidori, J Xie, ... Diabetologia 58, 1183-1187, 2015 | 162 | 2015 |
| Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes K Cusi, F Bril, D Barb, D Polidori, S Sha, A Ghosh, K Farrell, NE Sunny, ... Diabetes, Obesity and Metabolism 21 (4), 812-821, 2019 | 156 | 2019 |
| Effect of canagliflozin on liver function tests in patients with type 2 diabetes LA Leiter, T Forst, D Polidori, DA Balis, J Xie, S Sha Diabetes & metabolism 42 (1), 25-32, 2016 | 139 | 2016 |
| Roux-en-Y gastric bypass corrects hyperinsulinemia implications for the remission of type 2 diabetes MA Reed, WJ Pories, W Chapman, J Pender, R Bowden, H Barakat, ... The Journal of Clinical Endocrinology & Metabolism 96 (8), 2525-2531, 2011 | 134 | 2011 |
| Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes D Polidori, A Mari, E Ferrannini Diabetologia 57, 891-901, 2014 | 131 | 2014 |
| Determination of modal parameters from ambient vibration data for structural health monitoring JL Beck, BS May, DC Polidori First World Conference on Structural Control 2, 1994 | 119 | 1994 |
| Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double‐blind, crossover study S Sha, D Polidori, K Farrell, A Ghosh, J Natarajan, N Vaccaro, J Pinheiro, ... Diabetes, Obesity and Metabolism 17 (2), 188-197, 2015 | 112 | 2015 |
| Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus N Rosenthal, G Meininger, K Ways, D Polidori, M Desai, R Qiu, M Alba, ... Annals of the New York Academy of Sciences 1358 (1), 28-43, 2015 | 111 | 2015 |
| Clinical pharmacokinetic, pharmacodynamic, and drug–drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor D Devineni, D Polidori Clinical pharmacokinetics 54, 1027-1041, 2015 | 110 | 2015 |
